针对乳腺癌向治疗的铁氨酸激酶抑制剂的综述
Vidya Sankarapandian1, Ramya Lakshmi Rajendran2, Conrad Ondieki Miruka3
1Department of Microbiology and Immunology, Kampala International University, Western Campus, Box 20000, Uganda.
Pathology, research and practice
|September 26, 2024
概括
氨酸激酶抑制剂 (TKIs) 是乳腺癌的有效向疗法,破坏瘤生长途径. 本综述探讨了临床试验中的TKI,显示了改善的生存率和个性化乳腺癌治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌是一种具有分子异质性的复杂疾病.
- 过度表达的氨酸激酶受体与预后不佳有关,使它们成为治疗点.
- 氨酸激酶抑制剂 (TKIs) 破坏瘤生长和扩散的关键途径.
研究的目的:
- 审查当前和新兴的铁激酶抑制剂 (TKI) 用于乳腺癌治疗.
- 探索技术知识在临床前研究和临床试验中的作用.
- 讨论将TKI整合到个性化乳腺癌治疗中.
主要方法:
- 对乳腺癌中TKIs的临床前研究和临床试验的文献综述.
- 针对受体氨酸激酶 (例如,HER2,EGFR,VEGFR) 的TKI机制的分析.
- 检查与化疗,内分泌疗法或其他向药物联合使用时的TKI疗效.
主要成果:
- 针对各种铁酸激酶 (HER2,EGFR,VEGFR,ALK,RET,FGFR,ROS1,MAPK,TRK) 的TKI在乳腺癌中至关重要.
- 已批准的TCI如拉帕提尼布,内拉提尼布和图卡提尼布可以改善无进展和整体存活率.
- 作为治疗各种乳腺癌亚型的治疗选择,TKI显示出希望.
结论:
- 技术知识介绍器代表了针对性乳腺癌治疗的重大进步.
- 涉及TKI的组合疗法可以改善患者的治疗结果.
- 未来的乳腺癌治疗可能会涉及新的技术知识和个性化策略.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
146
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
146
Receptor Tyrosine Kinases
12.5K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


